The Effect of Acupuncture Therapy on Cognitive Function in Post-COVID-19 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NCT07357688, Not applicable, Not yet recruiting, Xi Wu
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Effect of Acupuncture Therapy on Cognitive Function in Post-COVID-19 Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | ClinicalTrials.gov |
| NCT number | NCT07357688 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 99 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Xi Wu | ClinicalTrials.gov |
| Conditions | Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | ClinicalTrials.gov |
| Interventions | Acupuncture, Sham acupuncture | ClinicalTrials.gov |
| First posted | 2026-01-22 | ClinicalTrials.gov |
| Last updated | 2026-01-22 | ClinicalTrials.gov |
Registered outcomes 23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change of Symbol Digit Modality Test score from baseline to the end of 8 weeks | Baseline and 8 weeks | Symbol Digit Modality Test assesses attention through measuring the number of correct responses within 90 seconds. The minimum score is 0, and the maximum score is 110. Higher score indicates better attention. | ClinicalTrials.gov |
| Secondary | Changes of Digit Span Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Digit Span Test consists of forward and backward subtests, that respectively assess attention and executive function through measuring the number of correct digit sequences. The minimum score is 0 , and the maximum scores are respectively 10 and 9 for forward and backward subtests. Higher scores indicate better attention and executive function. | ClinicalTrials.gov |
| Secondary | Changes of Trail Making Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Trail Making Test includes Part A(TMT-A) and Part B(TMT-B), that respectively evaluates attention and executive function via measuring the time in seconds required for completion of each part of the test. Higher scores indicate worse attention and executive function. | ClinicalTrials.gov |
| Secondary | Changes of Rey Auditory Verbal Learning Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Rey Auditory Verbal Learning Test evaluates different aspects of verbal memory through measuring total learning, repetitions, delayed recall, retroactive interference, and proactive interference. Higher scores for total learning and delayed recall indicate better memory, while higher scores for repetitions, retroactive interference, and proactive interference indicate worse memory. | ClinicalTrials.gov |
| Secondary | Changes of Stroop Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Stroop test consists of Stroop word test(Part A), Stroop color test(Part B) and Stroop color word test(Part C), that assess executive function through measuring the time in second required to complete each part and the number of errors for each part. Higher score for each part indicates worse executive function. | ClinicalTrials.gov |
| Secondary | Changes of Rey-Osterrieth Complex Figure Test scores from baseline to the end of 8 weeks | Baseline and 8 weeks | Rey-Osterrieth Complex Figure Test evaluates visuospatial construction ability through measuring the accuracy of copy, and evaluates visual memory via measuring the accuracies of immediate and delayed recalls. Higher scores indicate better visuospatial construction and visual memory. | ClinicalTrials.gov |
| Secondary | Change of Verbal Fluency Test Scores from baseline to the end of 8 weeks. | Baseline and 8 weeks | Verbal Fluency Test includes Phonemic Fluency Test, Category Fluency Test and Action Fluency Test, that evaluate language. Verbal Fluency Test measures the number of correct words produced under restricted search conditions of phonemic(letter F), category(animals) and action(kitchen actions). Higher score for each subtest indicates better language. | ClinicalTrials.gov |
| Secondary | Change of Boston Naming Test from baseline to the end of 8 weeks | Baseline and 8 weeks | Boston Naming Test includes 30 items and evaluates language through measuring the total of correct responses. The minimum score is 0, and the maximum score is 30. Higher score indicates better language. | ClinicalTrials.gov |
| Secondary | Change of Multidimensional Fatigue Inventory score from baseline to the end of 8 weeks | Baseline and 8 weeks | Multidimensional Fatigue Inventory is a self-report instrument consisting of 20-item devised to evaluate fatigue through measuring the dimensions of General Fatigue, Physical Fatigue, Mental Fatigue, Reduced Motivation and Reduced Activity. The minimum score is 20 ,and the maximum score is 100. Higher score indicate greater severity of fatigue. | ClinicalTrials.gov |
| Secondary | Change of Pittsburgh Sleep Quality Index from baseline to the end of 8 weeks | Baseline and 8 weeks | Pittsburgh Sleep Quality Index is a self-report questionnaire with 19 items, that assesses general sleep quality within 1 month through measuring the components of Subjective Sleep Quality, Sleep Latency, Sleep Duration, Habitual Sleep Efficiency, Sleep Disturbances, Use of Sleeping Medication, and Daytime Dysfunction. The total score ranges from 0 to 21. Higher score indicates worse sleep quality. | ClinicalTrials.gov |
| Secondary | Change of the Generalized Anxiety Disorde-7 score from baseline to the end of 8 weeks | Baseline and 8 weeks | Generalized Anxiety Disorde-7 is a self-report questionnaire with 7 items, that assesses the level of anxiety in the past two week. The minimum score is 0, and the maximum score is 21. Higher score indicates greater severity of anxiety. | ClinicalTrials.gov |
| Secondary | Change of Hamilton Depression Scale from baseline to the end of 8 weeks | Baseline and 8 weeks | Hamilton Depression Scale is the most commonly used instrument for the assessment of depression in clinical practice. It includes 24 items and assesses the level of depression through measuring factors of Anxiety/Somatization, Weight, Cognitive Impairment, Diurnal Variation, Retardation, Sleep Disturbance, and Hopelessness. The total score range is 0 to 76. Higher total score indicates greater level of depression. | ClinicalTrials.gov |
| Secondary | Change of the MOS Item Short From Health Survey from baseline to the end of 8 weeks | Baseline and 8 weeks | The MOS Item Short From Health Survey is a self-report instrument with 36 items, that assesses quality of life through measuring subscales of Physical Function, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Higher subscores indicate better quality of life. | ClinicalTrials.gov |
| Secondary | The change in level of N-acetylaspartate(NAA)at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks. | The level of NAA will be represented as the NAA to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS). | ClinicalTrials.gov |
| Secondary | The change in level of choline(Cho)at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of Cho will be represented as the Cho to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
| Secondary | The change in level of glutamate (Glu) at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of Glu will be represented as the Glu to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
| Secondary | The change in level of glutamine (Gln) at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of Gln will be represented as the Gln to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
| Secondary | The change in level of lactate (Lac) at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of Lac will be represented as the Lac to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
| Secondary | The change in level of myo-inositol (mI) at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of mI will be represented as the mI to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
| Secondary | The change in level of glycerophosphorylcholine (GPC) at each hippocampus from baseline to the end of 8 weeks. | Baseline and 8 weeks | The level of GPC will be represented as the GPC to total creatine (Cr) ratio which is measured by Proton Magnetic Resonance Spectroscopy(MRS) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 42383026 | DERIVED | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 9
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Category Fluency | Secondary outcome | ConductCognition |
| Complex Figure Copy and Recall | Secondary outcome | ConductCognition |
| Digit Span Test | Secondary outcome | ConductCognition |
| Picture Naming Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)